Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8485260 | Tuberculosis | 2016 | 11 Pages |
Abstract
Current methods available highlight limitations in the clinical effectiveness literature, model structures and assumptions, which impact on the robustness of the cost-effectiveness results. These models available are useful, but limited on the information that can be used to inform on future cost-effectiveness analysis. Until consideration is given on deriving the performance of tests used to identify LTBI that progresses to active TB, and the development of more comprehensive models, the economic benefit of LTBI testing with TST/IGRAs in high risk populations will remain unanswered.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Peter Auguste, Alexander Tsertsvadze, Rachel Court, Joshua Pink,